Tekturna - 2007 FDA approvals

Drug: Tekturna (aliskiren)
Indication: Hypertension
Company: Novartis
Approval Date: March 5, 2007

Scoop: Tekturna is the first in a new class of drugs called direct renin inhibitors, which target an enzyme responsible for triggering a process that can contribute to high blood pressure. Novartis hopes that Tekturna will eventually replace the company's blockbuster drug Diovan--which does $4.22 billion in annual sales--when the patent on that drug expires.

More news:
FDA approves Novartis' Tekturna. Report

Image: Tekturna packaging

Tekturna - 2007 FDA approvals
Read more on

Suggested Articles

When it’s time to go public, most biotech companies for the Nasdaq. Not so for SQZ Biotech, which raised $71 million in its NYSE debut.

The saga of COVID antibody R&D continues as the REGN-COV2 antibody cocktail used by President Donald Trump has been hit by safety concerns.

A Dartmouth-led team proposed a method for targeting and inhibiting the most aggressive cells in breast tumors to improve responses to chemotherapy.